Fig. 6: Inhibiting branched N-glycans enhances the sensitivity of HR-proficient ovarian tumors to immune checkpoint blockade.

a Weight and images of orthotopic tumors formed by HR-proficient KPCA with shCtrl or shMGAT5 in C57BL/6 mice following the treatments with anti-PD-L1 antibody (n = 5 mice per group). Two-tailed P-values were calculated by ANOVA corrected by the Benjamini, Krieger and Yekutieli method to generate q-values. Error bars represent mean with SEM. b–d Weight and images of orthotopic tumors formed by HR-proficient KPCA (b) or UPK10 (c), or HR-deficient BPPNM (d) cells in C57BL/6 mice following the indicated treatments with 2DG, anti-PD-L1 antibody or in combination (n = 5 mice per group for anti-PD-L1 and the combination groups with exception of n = 4 mice per group for control and 2DG groups). Please note that the control and anti-PD-L1 treatment groups were the same as those presented in Fig. 2g, h as they were simultaneously performed. Two tailed P-values were calculated by ANOVA corrected by the Benjamini, Krieger and Yekutieli method to generate q-values. Error bars represent mean with SEM. Source data are provided as a Source Data file.